|
Patent landscape, scope, and claims summary: |
United States Patent 10,066,003 landscape analysis: SVLEKEIYSI (SEQ ID NO: 2) peptide-driven activated T-cell therapies for cancer
Executive summary
- US 10,066,003 claims two core inventions: (i) a method of treating specified cancers by administering a population of activated T cells that selectively recognize the peptide SVLEKEIYSI (SEQ ID NO: 2); and (ii) a related composition-driven method using a pharmaceutically acceptable salt form of the same peptide plus an adjuvant, to induce a T-cell response to that peptide across a broad cancer panel.
- The claim set is broad in cancer indication coverage and mechanistic scope (autologous/allogeneic; TIL/PBMC; expansion conditions; CD8 cytotoxic emphasis), while simultaneously locking in a narrow biochemical “signature” via the fixed 9–10 aa sequence SVLEKEIYSI and a limited antigen-presentation activation framework (MHC I, antigen presenting cell, optional recombinant-virus infection).
- The landscape risk for competitors is concentrated in two technical “hinges”: (a) using the same epitope (or close functional equivalents framed as recognizing the same aberrantly expressed peptide/MHC I presentation); and (b) matching the claimed immunoactivation recipe (adjuvant sets, expansion cytokines/CD28, dendritic-cell activation via peptide-MHC I or virus expressing the peptide).
- Enforcement leverage, if asserted, would likely focus on the epitope match and the clinical use of activated T cells or peptide-adjuvant formulations to induce peptide-specific cytotoxic T-cell responses in the listed cancers, not on manufacturing per se.
What does US 10,066,003 claim about SVLEKEIYSI-specific activated T cells for cancer treatment?
Core claim 1: A method of treating cancer by administering a population of activated T cells that selectively recognize cells aberrantly expressing the peptide with amino-acid sequence SVLEKEIYSI (SEQ ID NO: 2), with cancer selected from a long list spanning solid tumors and hematologic malignancies.
Key claim elements (claim 1 and its dependent set)
- Therapeutic modality: activated T cells (not restricted to CAR-T, TCR-T, or bispecific formats).
- Antigen specificity: fixed peptide sequence SVLEKEIYSI and “aberrantly expresses” phrasing.
- Activation state: “activated T cells,” further constrained by later claims to MHC class I presentation context and in vitro activation.
- Source options (dependent): autologous, healthy donor, derived from TILs or PBMCs.
- Manufacturing options (dependent): in vitro expansion; expansion with anti-CD28 and IL-12.
- Immune subset (dependent): includes CD8-positive cells.
- Delivery format (dependent): administered as a composition; composition may include an adjuvant.
- Adjuvant menu (dependent): wide selection including immune modulators and combination agents:
- Imiquimod
- Resiquimod
- GM-CSF
- Cyclophosphamide
- Sunitinib
- Bevacizumab
- Interferon-alpha
- CpG oligonucleotides and derivatives
- Poly(I:C) and derivatives
- RNA
- Sildenafil
- Particulate formations with PLG and virosomes
- Activation method details (dependent claims 9-14):
- cytotoxic T cells produced by contacting T cells with an antigen presenting cell presenting the peptide in a complex with MHC class I.
- optional antigen presenting cell infected with a recombinant virus expressing the peptide.
- antigen presenting cell is dendritic cell or macrophage.
- contacting can be in vitro.
Claim 1’s practical claim boundary
- The claim is not limited to a particular cancer biomarker other than the presence of aberrant SVLEKEIYSI expression on cancer cells.
- It also does not confine the exact T-cell engineering modality beyond activation and recognition. This increases potential coverage across formats that ultimately yield T cells capable of recognizing SVLEKEIYSI peptide-MHC I on target cells.
How broad is the cancer coverage in US 10,066,003, and what does that mean for infringement risk?
Broad indication sweep (claim 1) covers:
- Solid tumors: HCC, CRC, GB, GC, esophageal, NSCLC, PC, RCC, PCA, OC, melanoma, BRCA, SCLC, GBC/CCC, UBC, UEC
- Also includes benign prostate hyperplasia (BPH) (unusual for epitope tumor immunotherapy coverage; indicates claim language is not restricted to malignant-only settings for prostate)
- Hematologic malignancies: CLL, MCC, NHL, AML
Dependent scope includes claim 15-16 selecting NSCLC and CRC; and claim 17 recites essentially the same cancer panel for the peptide+adjuvant composition route.
Infringement implication
- The claim’s cancer list can function as a “universal hook” for a multi-indication therapy. If any clinical program uses SVLEKEIYSI-recognizing activated T cells in any listed cancer, the cancer-selection element can be satisfied even if the program’s primary target is narrower.
- For generic or follow-on immunotherapy programs, the key freedom-to-operate question becomes whether they can avoid either:
- the SVLEKEIYSI epitope as the recognized antigen (or the claimed “aberrantly expressed peptide”), or
- the claimed activated T-cell administration framework (including cytotoxic response induced by peptide-MHC I presentation, with the described activation conditions).
What composition claims does US 10,066,003 add beyond the activated T-cell method?
Core claim 17: A method for treating the same cancer panel by administering a composition comprising:
- the peptide SVLEKEIYSI (SEQ ID NO: 2) in a pharmaceutically acceptable salt form, and
- an adjuvant,
to induce a T-cell response to that peptide across the enumerated cancers.
Dependent claims 18-20 narrow functionality and indication
- Claim 18: T-cell response is cytotoxic.
- Claim 19-20: cancer narrowed to NSCLC and CRC respectively.
Regulatory and development implication
- The composition claim targets peptide-adjuvant immunization approaches, which may include direct peptide vaccination and immune-modulator co-administration.
- This is an IP bifurcation: one path is “activated T cells recognize SVLEKEIYSI”; the other is “peptide+adjuvant induces SVLEKEIYSI-specific T-cell response.”
What are the critical “technical hinges” for claim construction and enforcement for US 10,066,003?
1) The epitope lock: SVLEKEIYSI (SEQ ID NO: 2)
- The claims repeatedly fix the peptide sequence. That strongly anchors novelty and enforcement around epitope identity.
- Competitor avoidance typically requires:
- using a different peptide sequence, or
- using a strategy that does not rely on inducing/selecting T cells that “selectively recognize” cells expressing the specific SVLEKEIYSI peptide.
2) MHC class I linkage and antigen presentation context
- Claim 9 ties cytotoxic T-cell production to peptide in a complex with MHC class I on an antigen presenting cell.
- Claim 10 adds an option where the antigen presenting cell is infected with a recombinant virus expressing the peptide.
- A competitor using alternative antigen presentation (e.g., exogenous loading without the claimed “contacting” framework) might still risk capture if the biological outcome matches claim language.
3) Activated T-cell characterization
- The claim requires “activated” T cells. Dependent claims narrow the means: contacting T cells with peptide-MHC I expressing antigen presenting cells; optional recombinant virus; and specific expansion conditions (anti-CD28 + IL-12).
- In practice, the enforceability will turn on what constitutes “activated” and “selectively recognize” under the claim construction standard applied by the forum.
4) Adjuvant selection
- Dependent claim 8 contains a broad list of immune-active agents and drug/adjuvant categories (CpG, poly(I:C), cytokines, checkpoint-adjacent small molecules, oncolytics, particulate delivery, virosomes).
- The breadth increases coverage across co-formulation or regimen selections that include one or more of the enumerated adjuvants.
Which claim dependencies most likely matter for patent strength and litigation leverage?
Most litigation-relevant dependent features
- anti-CD28 + IL-12 expansion (claim 12): tends to be a clear, documentable manufacturing parameter.
- CD8-positive cytotoxic T cells (claims 13 and 18): easier to measure phenotypically and functionally.
- dendritic cell or macrophage antigen presenting cells (claim 11): narrows the biological mechanism.
- MHC class I peptide complex requirement (claim 9): narrows antigen presentation framing.
- recombinant virus expressing the peptide (claims 10, 11): adds a concrete activation method.
- adjuvant list (claim 8) and peptide salt form (claim 17): helps with identifying accused compositions/regimens.
Less likely leverage points
- Autologous vs healthy donor (claims 2-3): typically common in T-cell therapy practice; disputes may pivot on product-specific collection/manufacturing facts.
- In vitro expansion and contacting in vitro (claims 5 and 14): common; may not add much unless accused product uses non-in vitro activation.
What are the likely prior-art and obviousness attack surfaces for US 10,066,003?
Without the patent file wrapper, office actions, or the full specification text, the strongest analytical approach is to identify typical attack vectors aligned with the claim structure:
- Epitope novelty
- The single biggest vulnerability is if SVLEKEIYSI (SEQ ID NO: 2) is disclosed as a known T-cell epitope in prior literature or prior patents for cancer immunotherapy, especially with MHC class I context.
- If prior art already taught using this epitope (or a substantially identical epitope under same MHC restriction) to activate cytotoxic T cells, claim 1 and claim 17 would face obviousness risk.
- Combination of known immunological steps
- Claim 1 combines: epitope-specific targeting + activated T cells + optional autologous/TIL/PBMC sources + IL-12 and anti-CD28 expansion.
- Those elements individually are widely used in immunotherapy manufacturing and could be characterized as routine optimization if SVLEKEIYSI was already known.
- Adjuvant list breadth
- Dependent claim 8 enumerates many agents used as immune stimulators or regimen components.
- If prior art taught the same peptide with typical adjuvants (CpG, poly(I:C), GM-CSF, interferon-alpha, imiquimod, cyclophosphamide, IL-12, etc.), claim 8 could be challenged as obvious.
- Peptide salt form
- Claim 17 requires a pharmaceutically acceptable salt. Salt forms are often considered routine unless the specification shows a specific unexpected property.
What generic or follow-on entry risks exist for peptide-adjuvant and activated T-cell programs covering SVLEKEIYSI?
1) “Generic” mismatch reality
- In practice, there is no conventional generic for an activated T-cell therapy or an epitope peptide vaccine coupled with adjuvants. Competition is more likely to arrive via:
- alternative manufacturing (different activation methods),
- alternative epitope selection (different peptides),
- alternative delivery vectors (different recombinant virus or expression system),
- alternative adjuvants not in the list, or
- alternative immune pathways that do not rely on SVLEKEIYSI-specific T-cell recognition as claimed.
2) High-risk competitive designs
- Any program that:
- uses SVLEKEIYSI peptide (or a salt form) as the intended T-cell antigen,
- uses CpG/poly(I:C)/PLG/virosome or other enumerated adjuvants,
- or generates CD8 cytotoxic T cells using peptide-MHC I antigen-presenting cell stimulation,
will have material infringement exposure.
3) Lower-risk designs
- Avoidance pathways are typically:
- replacing SVLEKEIYSI with a different epitope,
- limiting therapy to non-listed cancers (if regulatory indication can avoid the claim’s “selected from the group consisting of…” element, though drug labeling does not always avoid infringement),
- using an adjuvant outside the claim 8 enumerated set while still achieving a similar immune response (though literal infringement depends on whether the claim requires the specific adjuvants).
How strong is the patent estate likely to be for US 10,066,003, given claim structure?
Strength indicators from the claim set
- Tight epitope definition (sequence specificity) creates a clean claim anchor.
- Multiple dependent claims recite detailed, checkable biological processes (MHC I peptide complex presentation, APC types, recombinant virus expression, CD8 cytotoxic response, IL-12 + anti-CD28 expansion).
- The dual claim strategy (activated T cells plus peptide+adjuvant induction) raises the probability of capturing more than one therapy modality that uses the same antigen.
Strength limitations from breadth and routine immune engineering
- The adjuvant list breadth and the common nature of TIL/PBMC sources, CD28 signaling, and IL-12 risk “routine combination” arguments.
- If SVLEKEIYSI is widely disclosed in the art, the novelty may be undermined.
What patent litigation and IPR tactics typically target epitope- and immunology-driven claims like these?
Common strategy sets in US immunotherapy disputes:
- Claim construction fights around:
- “selectively recognize” (threshold and specificity),
- “aberrantly express” (what level or cell-type counts),
- “activated” (functional vs phenotypic definition).
- Prior art mapping for:
- epitope sequence disclosure,
- peptide-MHC I stimulation of CD8 cytotoxic T cells,
- antigen presentation with dendritic cells/macrophages,
- recombinant virus expressing a defined peptide.
- Obviousness based on:
- combining an epitope reference with standard immunotherapy activation/adjuvant recipes.
What does the Orange Book status of US 10,066,003 likely imply?
Nothing can be concluded from the patent number alone about Orange Book listing because Orange Book status depends on whether US 10,066,003 is listed for a particular FDA-approved drug product with marketing authorization. Without the FDA reference product linkage (NDA/BLA and listing metadata), an Orange Book-driven exclusivity analysis cannot be produced from the claim text provided.
Commercial landscape: where US 10,066,003 is most likely to intersect real-world programs
Even without naming specific assignees in the record here, the claim structure points to two commercial “intersection zones”:
- Epitope peptide vaccine programs
- Programs that market a peptide antigen matching SVLEKEIYSI plus an adjuvant matching or overlapping the claim list.
- Cell therapy programs that generate epitope-specific CD8 cytotoxic T cells
- Autologous or donor-derived activated T cells where SVLEKEIYSI is the antigen target presented via MHC I and where IL-12 + anti-CD28 expansion or equivalent activation is used.
Key takeaways
- US 10,066,003 is anchored on a single defined epitope, SVLEKEIYSI (SEQ ID NO: 2), and covers cancer immunotherapy by two routes: (1) administering activated, peptide-recognizing T cells and (2) administering a peptide+adjuvant composition that induces a peptide-specific cytotoxic T-cell response.
- The indication list is broad, and the claim dependencies add concrete, testable immunological and manufacturing-style parameters (MHC I complex presentation, dendritic cell/macrophage APC, recombinant virus expressing the peptide, CD8 cytotoxic framing, IL-12 + anti-CD28 expansion, and enumerated adjuvants).
- Competitive freedom-to-operate is most sensitive to epitope identity (SVLEKEIYSI) and to whether the accused therapy uses peptide-MHC I activation and the claimed adjuvant framework to produce SVLEKEIYSI-specific cytotoxic T cells.
FAQs
-
Can a therapy that uses SVLEKEIYSI but with a different T-cell activation schedule avoid infringement?
If it still administers activated T cells that selectively recognize SVLEKEIYSI-expressing cells under the claim’s definition, schedule differences may not avoid capture.
-
Does using an adjuvant not listed in claim 8 eliminate exposure under claim 17?
Claim 17 requires an “adjuvant” generally, while claim 8 narrows to a specific list only for the dependent path. Exposure depends on which claims are asserted and the exact adjuvant choice.
-
What is the main difference between claim 1 and claim 17 in product targeting?
Claim 1 targets administration of activated T-cell populations specific for SVLEKEIYSI; claim 17 targets peptide-salt plus adjuvant administration that induces T-cell responses to the peptide.
-
How does the MHC class I requirement affect competitor designs?
Designs that do not rely on peptide presentation in an MHC class I context for generating cytotoxic recognition are a potential avoidance path, but the biological outcome can still align with claimed function.
-
Is the broad cancer list a meaningful defense for companies limiting indications?
Limiting labeling may not fully avoid infringement if the accused therapy, in practice, treats cancers within the claimed enumerated set.
References
- USPTO Patent US 10,066,003 (claims provided in prompt).
More… ↓
⤷ Start Trial
|
